tetano
Editor, Senior Moderator
Vaccines (Basel). 2020 Feb 9;8(1). pii: E78. doi: 10.3390/vaccines8010078. [h=1]Predominance of a Drifted Influenza A (H3N2) Clade and its Association with Age-specific Influenza Vaccine Effectiveness Variations, Influenza Season 2018-2019.[/h]
Glatman-Freedman A[SUP]1,[/SUP][SUP]2[/SUP], Pando R[SUP]1,[/SUP][SUP]3[/SUP], Sefty H[SUP]1[/SUP], Omer I[SUP]2[/SUP], Rosenberg A[SUP]1[/SUP], Drori Y[SUP]2,[/SUP][SUP]3[/SUP], Nemet I[SUP]3[/SUP], Mendelson E[SUP]2,[/SUP][SUP]3[/SUP], Keinan-Boker L[SUP]1,[/SUP][SUP]4[/SUP], Mandelboim M[SUP]2,[/SUP][SUP]3[/SUP], Israeli Influenza Surveillance Network Iisn FT.
[h=3]Author information[/h]
[h=3]Abstract[/h] Background: Influenza A (H3N2) clade 3C.3a was the predominant influenza virus in Israel throughout the 2018-2019 season, constituting a drift from the influenza A (H3N2) vaccine. We estimated the end-of season vaccine effectiveness (VE) by age, among community patients with influenza-like illness (ILI), considering the hemagglutinin (HA) gene mutations and amino acid substitutions of influenza A (H3N2) viruses detected. Methods: Nose-throat samples were analyzed for the presence of influenza virus, type/subtype, and HA gene sequence. HA gene sequences and amino acid substitutions were compared to the influenza A/Singapore/INFIMH-16-0019/2016 (H3N2)-like 2018-2019 vaccine virus, and a phylogenetic tree was generated. Influenza VE against influenza A (H3N2) was estimated using the test-negative design. VE was estimated by age group and by 15 year moving age intervals. Results: In total, 90% of the influenza A (H3N2) viruses belonged to the 3C.3a clade, constituting a unique situation in the northern hemisphere. Adjusted all-age influenza A (H3N2) VE was -3.5% (95% CI: -51.2 to 29.1). Although adjusted VEs were very low among infants, children, and young adults, a VE of 45% (95% CI: -19.2 to 74.6) was estimated among adults aged ≥45 years old. Conclusions: The higher VE point estimates among older adults may be related to previous exposure to similar influenza viruses.
[h=4]KEYWORDS:[/h] drift; influenza A (H3N2); influenza vaccine; vaccine effectiveness
PMID: 32050460 DOI: 10.3390/vaccines8010078
Glatman-Freedman A[SUP]1,[/SUP][SUP]2[/SUP], Pando R[SUP]1,[/SUP][SUP]3[/SUP], Sefty H[SUP]1[/SUP], Omer I[SUP]2[/SUP], Rosenberg A[SUP]1[/SUP], Drori Y[SUP]2,[/SUP][SUP]3[/SUP], Nemet I[SUP]3[/SUP], Mendelson E[SUP]2,[/SUP][SUP]3[/SUP], Keinan-Boker L[SUP]1,[/SUP][SUP]4[/SUP], Mandelboim M[SUP]2,[/SUP][SUP]3[/SUP], Israeli Influenza Surveillance Network Iisn FT.
[h=3]Author information[/h]
[h=3]Abstract[/h] Background: Influenza A (H3N2) clade 3C.3a was the predominant influenza virus in Israel throughout the 2018-2019 season, constituting a drift from the influenza A (H3N2) vaccine. We estimated the end-of season vaccine effectiveness (VE) by age, among community patients with influenza-like illness (ILI), considering the hemagglutinin (HA) gene mutations and amino acid substitutions of influenza A (H3N2) viruses detected. Methods: Nose-throat samples were analyzed for the presence of influenza virus, type/subtype, and HA gene sequence. HA gene sequences and amino acid substitutions were compared to the influenza A/Singapore/INFIMH-16-0019/2016 (H3N2)-like 2018-2019 vaccine virus, and a phylogenetic tree was generated. Influenza VE against influenza A (H3N2) was estimated using the test-negative design. VE was estimated by age group and by 15 year moving age intervals. Results: In total, 90% of the influenza A (H3N2) viruses belonged to the 3C.3a clade, constituting a unique situation in the northern hemisphere. Adjusted all-age influenza A (H3N2) VE was -3.5% (95% CI: -51.2 to 29.1). Although adjusted VEs were very low among infants, children, and young adults, a VE of 45% (95% CI: -19.2 to 74.6) was estimated among adults aged ≥45 years old. Conclusions: The higher VE point estimates among older adults may be related to previous exposure to similar influenza viruses.
[h=4]KEYWORDS:[/h] drift; influenza A (H3N2); influenza vaccine; vaccine effectiveness
PMID: 32050460 DOI: 10.3390/vaccines8010078